iShares US Pharmaceuticals ETF
101 hedge funds and large institutions have $87.9M invested in iShares US Pharmaceuticals ETF in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 31 reducing their positions, and 9 closing their positions.
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
2% more funds holding
Funds holding: 99 → 101 (+2)
3% less capital invested
Capital invested by funds: $91M → $87.9M (-$3.08M)
1.81% less ownership
Funds ownership: 76.05% → 74.23% (-1.8%)
39% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$5.44M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.95M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.68M |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$458K |
| 5 |
LPL Financial
San Diego,
California
|
+$327K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.32M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.61M |
| 3 |
CG
Colony Group
Boston,
Massachusetts
|
-$1.01M |
| 4 |
PAG
Pinnacle Advisory Group
Columbia,
Maryland
|
-$713K |
| 5 |
Morgan Stanley
New York
|
-$357K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CWC
101
Carolinas Wealth Consulting
Charlotte,
North Carolina
| $1K | +$1.45K | +24 | New |
|
|
CG
102
Colony Group
Boston,
Massachusetts
| – | -$1.01M | -16,857 | Closed |
|
|
PAG
103
Pinnacle Advisory Group
Columbia,
Maryland
| – | -$713K | -11,919 | Closed |
|
104
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$315K | -5,274 | Closed |
|
|
CPSC
105
Carl P. Sherr & Co
Worcester,
Massachusetts
| – | -$220K | -3,681 | Closed |
|
|
SIAG
106
Safeguard Investment Advisory Group
Corona,
California
| – | -$156K | -2,607 | Closed |
|
|
FCH
107
Freestone Capital Holdings
Seattle,
Washington
| – | -$81.3K | -1,359 | Closed |
|
|
SSC
108
Syverson Strege & Co
West Des Moines,
Iowa
| – | -$73K | -1,215 | Closed |
|
|
CFA
109
Carroll Financial Associates
Charlotte,
North Carolina
| – | -$16K | -270 | Closed |
|
|
TPWA
110
TRUE Private Wealth Advisors
Salem,
Oregon
| – | -$7K | -120 | Closed |
|
IHE Hedge Fund Activity: Q1 2021 in Review
101 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2021, worth a combined $87.9M — down 3.4% from $91M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new IHE positions and 9 closed out — a net gain of 3 holders — while 19 added to existing stakes and 31 trimmed.
The largest buyer was Wells Fargo, adding an estimated $5.44M. The largest seller was Tower Research Capital (TRC), cutting an estimated $6.32M.
- 101 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2021, up from 99 in Q4 2020.
- Funds reported $87.9M of iShares US Pharmaceuticals ETF stock for Q1 2021, down 3.4% quarter-over-quarter.
- 12 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2021 and 9 closed out, a net change of +3 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2021 was Wells Fargo, an estimated $5.44M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2021 was Tower Research Capital (TRC), an estimated $6.32M sold.
Based on aggregated 13F filings for Q1 2021.